CN116121110A - 一种抑菌和抗炎作用较强的乳酸乳球菌yj0801及其应用 - Google Patents
一种抑菌和抗炎作用较强的乳酸乳球菌yj0801及其应用 Download PDFInfo
- Publication number
- CN116121110A CN116121110A CN202211340066.6A CN202211340066A CN116121110A CN 116121110 A CN116121110 A CN 116121110A CN 202211340066 A CN202211340066 A CN 202211340066A CN 116121110 A CN116121110 A CN 116121110A
- Authority
- CN
- China
- Prior art keywords
- lactococcus lactis
- strain
- intestinal
- inflammatory effects
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000014897 Streptococcus lactis Nutrition 0.000 title claims abstract description 84
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 17
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 15
- 241000194035 Lactococcus lactis Species 0.000 title claims abstract 10
- 230000000968 intestinal effect Effects 0.000 claims abstract description 25
- 239000001963 growth medium Substances 0.000 claims abstract description 11
- 241001465754 Metazoa Species 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 229920001817 Agar Polymers 0.000 claims abstract description 8
- 239000008272 agar Substances 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims abstract description 8
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 230000001580 bacterial effect Effects 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 238000003794 Gram staining Methods 0.000 claims description 2
- 230000037237 body shape Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 210000004051 gastric juice Anatomy 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 239000003242 anti bacterial agent Substances 0.000 abstract description 8
- 229940088710 antibiotic agent Drugs 0.000 abstract description 8
- 239000002253 acid Substances 0.000 abstract description 7
- 241000269417 Bufo Species 0.000 abstract description 6
- 206010009944 Colon cancer Diseases 0.000 abstract description 6
- 230000003115 biocidal effect Effects 0.000 abstract description 6
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 6
- 238000011084 recovery Methods 0.000 abstract description 6
- 244000052616 bacterial pathogen Species 0.000 abstract description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 5
- 239000003833 bile salt Substances 0.000 abstract description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 4
- 206010018910 Haemolysis Diseases 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000008588 hemolysis Effects 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 abstract 1
- 230000000789 acetogenic effect Effects 0.000 abstract 1
- 244000057717 Streptococcus lactis Species 0.000 description 74
- 241000894006 Bacteria Species 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 229920003045 dextran sodium sulfate Polymers 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 108020004465 16S ribosomal RNA Proteins 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 6
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000002949 hemolytic effect Effects 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 150000004666 short chain fatty acids Chemical class 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000009631 Broth culture Methods 0.000 description 5
- 241000606856 Pasteurella multocida Species 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 241000607447 Yersinia enterocolitica Species 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 229940051027 pasteurella multocida Drugs 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 229940098232 yersinia enterocolitica Drugs 0.000 description 5
- 241000186779 Listeria monocytogenes Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229960004755 ceftriaxone Drugs 0.000 description 4
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 235000021391 short chain fatty acids Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 208000036649 Dysbacteriosis Diseases 0.000 description 3
- 208000027244 Dysbiosis Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000577483 Salmonella enterica subsp. enterica serovar Paratyphi B Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000007140 dysbiosis Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960002626 clarithromycin Drugs 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-N isocaproic acid Chemical compound CC(C)CCC(O)=O FGKJLKRYENPLQH-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- -1 Acetic acid N-butyric acid Isobutyric acid 2-methylbutyric acid Isopentanoic acid Chemical compound 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000269420 Bufonidae Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- SCULJPGYOQQXTK-OLRINKBESA-N Cinobufagin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)C=CC(=O)OC=1 SCULJPGYOQQXTK-OLRINKBESA-N 0.000 description 1
- SCULJPGYOQQXTK-UHFFFAOYSA-N Cinobufagin Natural products CC(=O)OC1C2OC22C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 SCULJPGYOQQXTK-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000751185 Listeria monocytogenes ATCC 19115 Species 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 208000011140 intestinal infectious disease Diseases 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明公开了一种抑菌和抗炎作用较强的乳酸乳球菌(Lactococcus lactis)YJ0801及其应用。本发明提供的乳酸乳球菌菌株YJ0801,保藏号为CGMCC NO.25642。该菌株从采自自然保护区的中华蟾蜍(Bufo gargarizans)肠道中分离筛选得到,在MRS琼脂培养基上生长良好,没有溶血现象,对多种抗生素敏感,不携带抗生素抗性基因,对酸、胆盐、人工胃液、人工肠液有较好的耐受能力,对人结肠癌细胞HT‑29黏附能力强,产乙酸能力较好,对多种致病菌具有较强的抑制能力,对于服用过量抗生素引起的肠道菌群失调有促进菌群恢复作用,对DSS诱导的小鼠结肠炎模型有较好的预防和治疗效果,炎症指标明显降低。该菌株应用于食品或药品领域,不仅具有实际生产价值,而且对人和动物健康具有非常重要的意义。
Description
技术领域
本发明涉及微生物技术领域,特别是一种具有较强抑菌和抗炎作用的乳酸乳球菌YJ0801及其应用。
背景技术
中华蟾蜍(Bufo gargarizans)在我国分布广、数量多,对环境适应能力强,还是我国传统药用两栖动物,蟾酥、蟾衣均有悠久的药用历史。最近,我们对中华蟾蜍体表和肠道微生物进行了16S rRNA测序和宏基因组测序研究,发现蟾蜍体表和肠道微生物非常丰富,多达数千种,包括众多对人体和动物有益的益生菌类群,是十分珍贵的微生物资源库。
细菌性肠炎是多种细菌如大肠杆菌、沙门菌、梭菌、痢疾杆菌等感染引起的消化系统疾病(如小肠炎和结肠炎等),是人和家养动物的常见病,临床上主要使用各种抗生素进行治疗,但由于细菌容易产生抗生素抗性,常常达不到预期的效果。大量研究表明,乳酸菌作为益生菌的一类,被美国食品和药品监督管理局(FDA)认定是高度安全的食品级微生物。国内应用也越来越普遍,到目前为止,国家卫生健康委员会批准的《可用于食品的菌种名单》中共列入38种,其中包括大量乳酸菌,乳酸乳球菌也名列其中。作为肠道中的主要益生菌群之一,乳酸乳球菌可调节肠道菌群,可以抑制病原微生物的生长繁殖,所以利用乳酸乳球菌预防或抑制病原菌感染,调节肠道菌群结构已引起人们的广泛关注。因此,从中华蟾蜍(Bufo gargarizans)肠道中分离筛选抑菌抗炎能力强的乳酸菌,将其应用于功能性食品领域,具有广阔的应用前景。
发明内容
本发明的目的在于提供一种抑菌和抗炎作用较强的乳酸乳球菌YJ0801,并提供该乳酸乳球菌YJ0801在制备具有抑菌、抗炎及调节人和动物肠道菌群的功能性食品中的应用。
本发明的目的通过以下技术方案来实现:本发明提供一种抑菌和抗炎作用较强的乳酸乳球菌(Lactococcus lactis)YJ0801,其于2022年9月2日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏号为CGMCC NO.25642。
进一步的,所述乳酸乳球菌YJ0801是从自然保护区采集的野生中华蟾蜍消化道中分离筛选获得。
进一步的,所述乳酸乳球菌YJ0801通过采用细菌通用引物16S rRNA的27F/1492R对其基因组总DNA为模板进行PCR扩增,得到由1002碱基对(bp)组成的目的基因序列,序列如附表所示。将测序得到的基因序列输入NCBI数据库进行比对,其与GenBank中的标准菌株Lactococcus lactis strain Guimu 24相似率达99.90%,鉴定该菌株为乳酸乳球菌(Lactococcus lactis)。
进一步的,所述乳酸乳球菌YJ0801,在MRS琼脂培养基上生长良好,菌落为乳白色,表面光滑,边缘整齐,不透明,对菌体形态进行镜检,革兰氏染色呈紫色。
本发明还提供所述乳酸乳球菌YJ0801在制备具有抑菌、抗炎的组合物上的应用,所述组合物包括食品或药品。
本发明还提供所述乳酸乳球菌YJ0801在制备调节人和动物肠道菌群的组合物上的应用,所述组合物包括食品或药品。
进一步的,所述乳酸乳球菌YJ0801,对酸和胆盐有一定的耐受能力,对人结肠癌细胞HT-29黏附能力较强,产乙酸能力较强。
进一步的,所述乳酸乳球菌YJ0801,对乙型副伤寒沙门氏菌、大肠埃希氏菌、金黄色葡萄球菌、铜绿假单胞菌、单增李斯特菌、鼠伤寒沙门氏菌、多杀性巴氏杆菌、溶血性葡萄球菌、小肠结肠炎耶尔森氏菌具有抑菌能力。
进一步的,所述乳酸乳球菌YJ0801,对的肠道菌群失调有较好的促进菌群恢复作用。
进一步的,所述乳酸乳球菌YJ0801,对DSS小鼠结肠炎模型有较好的预防和治疗效果,炎症指标明显降低。
本发明具有以下优点:
1、本发明提供的乳酸乳球菌YJ0801,分离筛选自保护区野生中华蟾蜍消化道,在MRS琼脂培养基上生长良好,对酸和胆盐有较好的耐受能力,对人结肠癌细胞HT-29黏附能力强。
2、所述乳酸乳球菌YJ0801,对乙型副伤寒沙门氏菌、大肠埃希氏菌、金黄色葡萄球菌、铜绿假单胞菌、单增李斯特菌、鼠伤寒沙门氏菌、多杀性巴氏杆菌、溶血性葡萄球菌、小肠结肠炎耶尔森氏菌等常见肠道病原细菌抑菌能力较强。
3、本发明提供的乳酸乳球菌YJ0801,通过动物实验表明,对肠道菌群失调有较好的促进菌群恢复作用,对DSS小鼠结肠炎模型有较好的预防和治疗效果,炎症指标明显降低,因此,应用于食品或药品领域,不仅具有实际生产价值,而且对人和动物健康也具有非常重要的意义。
附图说明
图1为乳酸乳球菌YJ0801菌株与GenBank中其它菌株的系统进化关系图。
图2为本发明乳酸乳球菌YJ0801在MRS琼脂培养基上的菌落形态图。
图3为乳酸乳球菌YJ0801菌株的溶血性实验图。
图4为乳酸乳球菌YJ0801菌株发酵液短链脂肪酸GC-MS测定图
图5为乳酸乳球菌YJ0801促进抗生素引起的小鼠肠道菌群失调后的恢复
图6为乳酸乳球菌YJ0801预防和治疗DSS诱导结肠炎小鼠结肠HE染色。
具体实施方式
为使本发明实施方式的目的、技术方案和优点更加清楚,下面将结合本发明实施方式中的附图,对本发明实施方式中的技术方案进行清楚、完整地描述,显然,所描述的实施方式是本发明一部分实施方式,而不是全部的实施方式。凡在本发明原则之内,所做的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
下述实施例中所用方法如无特别说明均为常规方法,培养基中所涉及的百分比,均为质量体积比。
实施例1
乳酸乳球菌YJ0801的分离、筛选及分子生物学鉴定:
本发明提供一种抑菌和抗炎作用较强的乳酸乳球菌(Lactococcus lactis)YJ0801,其于2022年9月2日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏号为CGMCC NO.25642。
所述乳酸乳球菌YJ0801的16S rRNA序列如SEQ ID:1所示。
1.1、材料准备
中华蟾蜍采自四川自然保护区野生个体;
16s rRNA通用引物27F和1492R通用引物由生工生物工程(上海)有限公司合成,序列如下:
27F:5-AGAGTTTGATCMTGGCTCAG-3;
1492R:5-GGTTACCTTGTTACGACTT-3。
MRS肉汤培养基的配方(每升):酪蛋白酶消化物10.0g,牛肉膏粉10.0g,酵母膏粉4.0g,柠檬酸三铵2.0g,乙酸钠5.0g,硫酸镁0.2g,硫酸锰0.05g,磷酸氢二钾2.0g,葡萄糖20.0g,吐温-80,最终pH为5.7左右。使用时称取该品54.0g,加入蒸馏水或去离子水1L,分装于锥形瓶,于121℃高压条件灭菌15min。
1.2、具体方式
1.2.1乳酸菌的分离纯化:活体中华蟾蜍解剖后,取少量肠道内容物,接种于50mLMRS肉汤中,充分振荡混匀,置于37℃恒温摇床培养24h。吸取培养液1ml,采用10倍梯度稀释法,各取菌液20μL,涂布接种于含有CaCO3的MRS琼脂培养基平板上,37℃培养24h后,挑取有明显溶钙环、且形态各异的单菌落100个,连续纯化培养3次。将纯化后的菌株接种于600μLMRS肉汤培养基中,37℃摇床培养18h,加入400μL浓度50%的灭菌甘油,于-80℃超低温冰箱中冻存,作为初选菌株备用。
1.2.2耐酸耐盐菌株筛选:用盐酸和猪胆盐调节MRS肉汤培养基的酸碱度和盐度。将冻存的100株初选菌株分别活化培养后先接种于pH=3.0的MRS肉汤培养基中,37℃培养12h后,吸取1mL接种于盐浓度为0.3%的MRS肉汤培养基中,37℃培养12h后,吸取20μL涂布于MRS琼脂平板上,37℃培养24h后,观察菌落生长情况。结果表明,有62株在平板上长出菌落,符合肠道益生菌耐酸耐盐要求。从各平板上挑取10个单菌落,纯化后加50%的甘油-80℃冻存,作为耐酸、耐盐菌株供进一步评估使用。
1.2.3菌株鉴定:将冻存的耐酸耐盐菌株活化和增殖培养后,用天根细菌基因组DNA提取试剂盒提取菌株DNA,使用通用引物扩增16S rRNA序列,PCR扩增产物送生工生物工程(上海)有限公司测序。测序结果经NCBI BLAST比对,有12株为乳酸乳球菌(Lactococcuslactis),根据溶钙圈明显程度和耐酸耐盐培养后菌落生长情况,确定其中一株为进一步评估的候选菌株。该菌株扩增的16S rRNA序列长度为1005bp(序列附后),经NCBI BLAST比对,与GenBank中的Lactococcus lactis strain Guimu 24菌株相似率达99.90%,命名为乳酸乳球菌YJ0801,与GenBank中其它菌株的系统进化关系如图1所示。所述乳酸乳球菌YJ0801菌株在MRS琼脂培养基上生长良好,菌落形态乳白色、圆形凸起、边缘平整、表面光滑,如图2所示。革兰氏染色后,在光学显微镜下可见紫色菌体,革兰氏阳性,符合乳酸乳球菌特征,与分子生物学鉴定结果一致。
实施例2
乳酸乳球菌YJ0801菌株的安全性评估
2.1.溶血性实验:将乳酸乳球菌YJ0801菌株复苏培养后,划线接种于哥伦比亚血平板上,37℃培养24h后观测待测菌落周围是否出现溶血环,并用溶血性葡萄球菌(Staphylococcus haemolyticus ATCC 29970)标准菌株为溶血性阳性对照。溶血性实验结果表明,在乳酸乳球菌YJ0801菌落周围没有出现溶血现象,而在溶血性葡萄球菌菌落周围溶血现象明显可见,如图3所示,在图3中,左半边为溶血性葡萄球菌阳性对照;右半边为乳酸乳球菌YJ0801)。
2.2.抗生素抗性:采用纸片琼脂扩散法(K-B法)测试菌株的抗生素抗性。将所述乳酸乳球菌YJ0801菌株活化培养后,将活菌浓度调整至1×106CFU/mL,用无菌棉签将菌液均匀涂抹于MRS培养基平板表面,室温10min后放入药敏纸片,37℃培养24h后,用游标卡尺测量各药敏纸片周围的抑菌圈直径,每种抗生素重复3次,试验结果参照NCCLS标准判断菌株的药物敏感性,结果以敏感(S)、中介(I)和耐药(R)表示。如表1所示,所述乳酸乳球菌YJ0801对测试的四环素、氨苄西林、头孢曲松、克林霉素、克拉霉素和氯霉素等6种抗生素表现均为敏感(S),说明所述乳酸乳球菌YJ0801菌株的安全性。
表1乳酸乳球菌YJ0801菌株对几种抗生素的敏感性
编号 | 四环素 | 氨苄西林 | 头孢曲松 | 克林霉素 | 克拉霉素 | 氯霉素 |
YJ0801 | S | S | S | S | S | S |
实施例3
乳酸乳球菌YJ0801的细胞粘附性和胃肠液耐受性评估
3.1细胞粘附性试验:将待测菌株活化培养后挑单菌落接种于MRS肉汤培养基中,37℃恒温培养24h,-4℃、5000r/min条件下离心10min,弃上清后用无菌PBS缓冲液洗涤3次,调整菌悬液浓度至1×106CFU/mL,备用。人结肠癌细胞HT-29复苏后接种至细胞培养板,添加DMEM完全培养基后在37℃、5% CO2的培养箱中培养,每隔一天更换一次培养液。当细胞贴壁生长融合状态达70%-80%时,使用0.25%胰酶-EDTA混合消化液进行传代培养。培养完毕后用细胞血球计数板计数,将细胞浓度调整至5×106个/mL。每个细胞培养孔中加1mL细胞悬浮液,于37℃、5% CO2的培养箱中培养。待培养板中的细胞长至单层,弃掉DMEM培养液,用无菌PBS液冲洗3次,然后每孔加入1mL已制备好的待测菌悬液,轻微晃动细胞培养板,使菌液在细胞孔中分布均匀,从每孔中吸少量菌液用于平板计数,其结果作为菌悬液中的初始活菌数。将细胞板置于37℃孵育2h,弃去培养基并用无菌PBS缓冲液洗涤3次。使用0.7mL 0.25%胰蛋白酶-EDTA消化细胞10min,待细胞完全脱落后加入0.3mL DMEM培养液终止消化,吸取少量培养液进行平板计数,其结果作为黏附活菌数。并用标准菌株LGG作为对照。粘附率计算公式如下:
粘附率(%)=粘附乳酸菌的数目/初始接种数目×100%。
细胞粘附性试验结果见表2。所述乳酸乳球菌YJ0801对人结肠癌细胞HT-29的粘附率为92.05%,明显高于标准菌株LGG的粘附能力。
表2乳酸乳球菌YJ0801对人结肠癌细胞HT-29的粘附率
3.2模拟胃液、肠液耐受实验:模拟胃液和肠液购自上海源叶生物科技有限公司。人工胃液模拟液成分为稀盐酸、胃蛋白酶和氯化钠,最终pH 2.5;人工肠液模拟液成分为磷酸二氢钾和胰蛋白酶,最终pH 6.8。将所述乳酸乳球菌YJ0801菌株活化培养后,调整菌液浓度至1×108CFU/mL,取1mL菌液加入9mL模拟人工胃液液中,充分混匀后进行10倍梯度稀释,吸取20μL涂平板计活菌数,作为耐受人工胃液的初始活菌值;接菌的模拟胃液于37℃培养3h后,再次涂平板计活菌数,作为耐受人工胃液的结束活菌值。同理,将1mL浓度为1×108CFU/mL的所述乳酸乳球菌YJ0801发酵液加入9mL模拟肠液中,并进行活菌计数,37℃培养6h后再次计活菌数,计算存活率(存活率(%)=结束时活菌数/初始活菌数×100%)。
模拟胃液、肠液耐受实验结果见表3,结果表明,所述乳酸乳球菌YJ0801菌株对于人工模拟胃、肠液有较好的耐受能力,人工胃液中3h后存活率为85.0%,人工肠液6h后存活率为65.0%。
表3乳酸乳球菌YJ0801菌株对于人工模拟胃、肠液的耐受能力
菌株 | 模拟胃液3h存活率(%) | 模拟肠液6h存活率(%) |
乳酸乳球菌YJ0801 | 85.0 | 65.0 |
标准菌株LGG | 51.2 | 49.5 |
实施例4
乳酸乳球菌YJ0801菌株的抑菌活性评估
将乙型副伤寒沙门氏菌(Salmonella para-typhi B CMCCB 50094)、大肠埃希氏菌(Escherichia coli CMCCB 44102)、金黄色葡萄球菌(Staphylococcus aureus CMCCB50094)、铜绿假单胞菌(Pseudomonas aeruginosa CMCCB 10104)、单增李斯特菌(Listeriamonocytogenes ATCC 19115)、鼠伤寒沙门氏菌(Salmonella typhimurium ATCC 14028)、多杀性巴氏杆菌(Pasteurella multocida ATCC51689)、溶血性葡萄球菌(Staphylococcushaemolyticus ATCC29970)、小肠结肠炎耶尔森菌(Yersinia enterocolitica ATCC23715)分别接种于营养琼脂培养基,复苏并传代3次。吸取适量胰酪大豆胨液体培养基至离心管,将活化好的致病菌接种于肉汤培养基中,并调节菌液浓度达到1×108CFU/mL。吸取上述致病菌和肉汤的混合液1mL加至500mL灭菌后暂处于液体状态的营养培养基内(温度冷却至50℃左右),充分混匀后按每皿约20mL的量制平板,冷却凝固后,用直径6mm的打孔器在平板上打孔,吸取40μL的待测菌菌液(菌液浓度达到1×108CFU/mL)加入孔内,重复3次,于37℃培养24h后,用游标卡尺测量抑菌圈直径,并用LGG标准菌株为对照。
参见表4乳酸乳球菌YJ0801菌株的抑菌活性评估,结果表明,所述乳酸乳球菌YJ0801菌株的发酵液对乙型副伤寒沙门氏菌、大肠埃希氏菌、金黄色葡萄球菌、铜绿假单胞菌、单增李斯特菌、鼠伤寒沙门氏菌、多杀性巴氏杆菌、溶血性葡萄球菌、小肠结肠炎耶尔森氏菌等致病菌的生长具有较强的抑制活性,大多优于LGG标准菌株。
表4乳酸乳球菌YJ0801菌株的抑菌活性评估(直径:mm)
实施例5
乳酸乳球菌YJ0801菌株发酵液短链脂肪酸含量GC-MS测定
发酵液的制备:将所述乳酸乳球菌YJ0801保存菌株活化培养24h后,吸取4ul菌液加入到4mL肉汤培养基中,37℃培养24h备用。
短链脂肪酸的检测:检测仪器为日本岛津公司气质联用仪(GCMS-QP2010 Plus),色谱柱为美国RESTEK(瑞斯泰克)公司Rtx-5熔融石英毛细管柱(30m×0.25mm×0.25um)。GC升温程序为初始温度40℃保持5min,每分钟5℃升至150℃,然后以每分钟10℃升到280℃,并维持2min。载气为高纯氦气(纯度>99.999%),流速:1.0mL/min。MS条件:电离方式为EI;温度为200℃,接口温度220℃,质量扫描范围m/z 33-500。取发酵液4mL,加入浓度为200ug/mL 2-乙基丁酸内标液10ul,样品以分流模式1:3的方式进样1μL,溶剂延迟时间设定为0.1min,进样口温度270℃。5种短链脂肪酸(乙酸、正丁酸、异丁酸、异戊酸、异己酸)的浓度采用内标法计算(图4)。
测定结果表明所述乳酸乳球菌YJ0801菌株发酵液中含多种短链脂肪酸,其中乙酸含量最高,达到8.405ug/mL,其次是异戊酸0.207,此外还检测到三种丁酸(表5)。
表5乳酸乳球菌YJ0801菌株发酵液短链脂肪酸含量(ug/mL)
菌株号 | 菌种名 | 乙酸 | 正丁酸 | 异丁酸 | 2-甲基丁酸 | 异戊酸 |
YJ0801 | 乳酸乳球菌 | 8.405 | 0.055 | 0.077 | 0.075 | 0.207 |
实施例6
乳酸乳球菌YJ0801对大剂量抗生素使用后小鼠肠道菌群的恢复实验
购买雄性三周龄昆明小鼠12只(体重20克左右),随机分为3组:空白对照组CK0、LGG组和乳酸乳球菌YJ0801处理组,每笼4只,共3笼。常规方法适应性饲养1周后,空白对照组每天灌胃0.2mL生理盐水,其它两组每天每只灌胃0.2mL头孢曲松溶液(40mg/d),持续灌胃两周,两周结束后测定粪便16S rRNA。随后,每天给LGG组灌胃0.2mL LGG菌悬液,乳酸乳球菌处理组灌胃0.2mL乳酸乳球菌YJ0801菌株菌悬液,活菌数均为1×109CFU/mL),并在第3、第6和第9天测定粪便16S rRNA。
实验结果表明,处理组灌喂头孢曲松溶液(40mg/d)两周后,小鼠肠道菌群大大减少,物种多样性指数(Shannon指数)仅为0.1217(YJ0801组)和0.3631(LGG组),仅剩下一些对抗生素耐性较强的细菌,而空白对照组多样性指数为3.5296。停用抗生素后,灌喂LGG或乳酸乳球菌YJ0801三天后即可发现菌群明显恢复,6天后多样性指数分别为3.0669和3.2054,基本恢复正常,9天后肠道菌群完全恢复,多样性指数与对照非常接近,如图5。
实施例7
乳酸乳球菌YJ0801对小鼠结肠炎模型的预防和治疗作用试验
7.1、实验动物及分组
共60只小鼠,随机分成12笼,每笼5只。随机分为4组,每组3笼,分组包括空白对照组(CK)、自然恢复组(DSS)、标准菌株组(LGG)和YJ0801处理组。实验处理如表6所示。
表6动物实验处理
7.2、实验内容
葡聚糖硫酸钠盐溶液(DSS):无菌水溶解葡聚糖硫酸钠盐配制浓度3%的DSS溶液。
菌悬液的制备:将标准菌株LGG和YJ0801复苏并活化3代。将菌液于-4℃、6000r/min条件下离心5min,弃掉上清液。使用无菌PBS缓冲液重悬菌体,调节菌液浓度为5×109CFU/mL,低温保存备用。
实验期间,每天观察其活动状况、粪便状态、血便现象。在预防期和治疗期结束时,分别随机处死3只小鼠,取血进行血清炎症因子检测。新鲜血样用无菌离心管收集,3000r/min离心10min,获得血清。使用ELISA试剂盒(江苏晶美生物科技有限公司)测定血清的炎症因子(TNF-α、IL-6和IL-1β),操作步骤按照试剂盒说明书进行。与此同时,解剖剪取1cm结肠,用4%多聚甲醛固定液固定24h,经包埋切片和HE染色制片,在光学显微镜下观察小鼠结肠组织的病理变化。
血清炎症因子测定结果如表7所示。从表7可知,在预防期和治疗期TNF-α、IL-6和IL-1β三个炎症因子指标都明显低于DSS组,说明所述乳酸乳球菌YJ0801菌株对DSS诱导的小鼠结肠炎有明显的缓解作用;结肠组织学观察如图6所示,结果表明DSS诱导组小鼠结肠黏膜及肌层变薄,腺体层次减少,肠腔扩张,局部溃疡形成(图6A),而DSS诱导加乳酸乳球菌YJ0801处理的小鼠结肠未出现明显的组织异常和溃疡,仅见黏膜有少许慢性炎症细胞浸润(图6B),进一步证明了所述乳酸乳球菌YJ0801的抗炎作用,因此,将其应用于食品或药品领域,不仅具有广阔的应用前景,而且对人体健康十分有益。
表7小鼠血清炎症因子测定结果(pg/mL)
尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (5)
1.一种抑菌和抗炎作用较强的乳酸乳球菌(Lactococcus lactis)YJ0801,其特征在于:所述乳酸乳球菌YJ0801已于2022年9月2日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC NO.25642。
2.根据权利要求1所述的一种抑菌和抗炎作用较强的乳酸乳球菌YJ0801,其特征在于:所述乳酸乳球菌YJ0801,在MRS琼脂培养基上生长良好,菌落为乳白色,表面光滑,边缘整齐,不透明,对菌体形态进行镜检,革兰氏染色呈紫色。
3.权利要求1所述的一种抑菌和抗炎作用较强的乳酸乳球菌YJ0801的应用。
4.根据权利要求2所述的应用,其特征在于:所述应用为制备具有抑菌、抗炎的组合物上的应用,所述组合物包括食品或药品。
5.根据权利要求2所述的应用,其特征在于:所述应用为制备调节人和动物肠道菌群的组合物上的应用,所述组合物包括食品或药品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211340066.6A CN116121110A (zh) | 2022-10-28 | 2022-10-28 | 一种抑菌和抗炎作用较强的乳酸乳球菌yj0801及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211340066.6A CN116121110A (zh) | 2022-10-28 | 2022-10-28 | 一种抑菌和抗炎作用较强的乳酸乳球菌yj0801及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116121110A true CN116121110A (zh) | 2023-05-16 |
Family
ID=86298014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211340066.6A Pending CN116121110A (zh) | 2022-10-28 | 2022-10-28 | 一种抑菌和抗炎作用较强的乳酸乳球菌yj0801及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116121110A (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023471A2 (en) * | 1998-10-20 | 2000-04-27 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of a cytokine-producing lactococcus strain to treat colitis |
EP1862080A1 (en) * | 2006-05-31 | 2007-12-05 | Ajinomoto Co., Inc. | Protease-resistant bacteriocins produced by lactic acid bacteria and their use in livestock |
WO2008134450A2 (en) * | 2007-04-24 | 2008-11-06 | Kemin Industries, Inc. | Broad-spectrum antibacterial and antifungal activity of lactobacillus johnsonii d115 |
WO2009066537A1 (ja) * | 2007-11-19 | 2009-05-28 | Meiji Dairies Corporation | 免疫調節性機能誘導剤及び食品組成物 |
US20130336944A1 (en) * | 2010-12-17 | 2013-12-19 | Compagnie Gervais Danone | Lactococcus Lactis Strains for Use in Improving Digestive Condition |
EP3081227A1 (en) * | 2015-04-15 | 2016-10-19 | Institut National De La Recherche Agronomique | Lactococcus lactis producing tslp or il-25 and their uses as probiotics and therapeutics |
US20170106058A1 (en) * | 2014-04-08 | 2017-04-20 | Lysando Ag | Pharmaceutical composition against chronic bacterial infections |
WO2019199048A1 (en) * | 2018-04-12 | 2019-10-17 | Genome And Company | Lactococcus lactis gen3013 strain and a composition for preventing or treating cancer comprising the same |
KR102121568B1 (ko) * | 2019-02-19 | 2020-06-10 | 삼육대학교산학협력단 | 클로스트리듐 디피실에 대해 항균 활성을 갖는 신규 페디오코쿠스 에시디락티시 spm138 및 이를 포함하는 조성물 |
WO2021040086A1 (ko) * | 2019-08-28 | 2021-03-04 | (주)네오리젠바이오텍 | 신규한 유산균, 이를 포함하는 조성물 및 건강기능식품 |
-
2022
- 2022-10-28 CN CN202211340066.6A patent/CN116121110A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023471A2 (en) * | 1998-10-20 | 2000-04-27 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of a cytokine-producing lactococcus strain to treat colitis |
EP1862080A1 (en) * | 2006-05-31 | 2007-12-05 | Ajinomoto Co., Inc. | Protease-resistant bacteriocins produced by lactic acid bacteria and their use in livestock |
WO2008134450A2 (en) * | 2007-04-24 | 2008-11-06 | Kemin Industries, Inc. | Broad-spectrum antibacterial and antifungal activity of lactobacillus johnsonii d115 |
WO2009066537A1 (ja) * | 2007-11-19 | 2009-05-28 | Meiji Dairies Corporation | 免疫調節性機能誘導剤及び食品組成物 |
US20130336944A1 (en) * | 2010-12-17 | 2013-12-19 | Compagnie Gervais Danone | Lactococcus Lactis Strains for Use in Improving Digestive Condition |
US20170106058A1 (en) * | 2014-04-08 | 2017-04-20 | Lysando Ag | Pharmaceutical composition against chronic bacterial infections |
EP3081227A1 (en) * | 2015-04-15 | 2016-10-19 | Institut National De La Recherche Agronomique | Lactococcus lactis producing tslp or il-25 and their uses as probiotics and therapeutics |
WO2019199048A1 (en) * | 2018-04-12 | 2019-10-17 | Genome And Company | Lactococcus lactis gen3013 strain and a composition for preventing or treating cancer comprising the same |
KR102121568B1 (ko) * | 2019-02-19 | 2020-06-10 | 삼육대학교산학협력단 | 클로스트리듐 디피실에 대해 항균 활성을 갖는 신규 페디오코쿠스 에시디락티시 spm138 및 이를 포함하는 조성물 |
WO2021040086A1 (ko) * | 2019-08-28 | 2021-03-04 | (주)네오리젠바이오텍 | 신규한 유산균, 이를 포함하는 조성물 및 건강기능식품 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115786198B (zh) | 一株副干酪乳杆菌及其应用 | |
CN113832077B (zh) | 鼠李糖乳杆菌及其应用 | |
WO2022236935A1 (zh) | 一种具有抑制奇异变形杆菌生长作用的益生菌及其发酵液和应用 | |
CN115851500B (zh) | 一株植物乳杆菌及其应用 | |
CN114634901B (zh) | 一种促进骨骼健康的干酪乳杆菌lc16及其培养方法与应用 | |
CN110157645B (zh) | 一种唾液乳杆菌y4及其应用 | |
CN115747111B (zh) | 一株戊糖片球菌及其应用 | |
CN114350578B (zh) | 一株产溶菌酶并高效拮抗多药耐药幽门螺杆菌的植物乳杆菌lp1z及其应用 | |
CN109182164B (zh) | 一株罗伊氏乳杆菌及其在蜜蜂养殖过程中的应用 | |
CN113736683A (zh) | 一株抑制幽门螺杆菌的嗜热链球菌及其应用 | |
CN115029260A (zh) | 一种具有抗炎及抗氧化特性的格氏乳杆菌及应用 | |
CN111000244A (zh) | 一种可改善肠道健康的干酪乳杆菌及其应用 | |
CN116083325B (zh) | 一种改善幽门螺杆菌相关性胃肠疾病的鼠李糖乳杆菌及其应用 | |
CN117143767A (zh) | 可调节肠道菌群的母乳源发酵粘液乳杆菌msjk0025及其应用 | |
CN114806953B (zh) | 一种具有改善1型糖尿病特性的格氏乳杆菌 | |
CN115029266B (zh) | 一株干酪乳杆菌m502及其与副干酪乳杆菌的复合制剂和在抗幽门螺杆菌药物中的应用 | |
CN111004735A (zh) | 一株发酵乳杆菌及其在改善肠道健康方面的应用 | |
CN113061550B (zh) | 一株乳杆菌新菌株z6及其在食品中的应用 | |
CN112063566B (zh) | 一株屎肠球菌及其应用 | |
CN116121110A (zh) | 一种抑菌和抗炎作用较强的乳酸乳球菌yj0801及其应用 | |
CN109161501B (zh) | 一种饲用地衣芽孢杆菌及其应用 | |
CN111004734A (zh) | 一种能够调控肠道中不动杆菌属相对丰度的鼠李糖乳杆菌 | |
CN114395514B (zh) | 一株嗜酸乳杆菌、菌剂及其应用 | |
CN117089505B (zh) | 一种副干酪乳杆菌vb306及其应用 | |
CN115029265B (zh) | 一株植物乳杆菌m503及其与鼠李糖乳杆菌复配的制剂和在抗幽门螺杆菌药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |